We are live on ! Find out more
PCMI

Paradigm Capital Management Inc Portfolio holdings

AUM $2.61B
1-Year Est. Return 78.58%
This Fund
S&P 500
This Quarter Est. Return
+21.32%
1 Year Est. Return
+78.58%
3 Year Est. Return
+164.7%
5 Year Est. Return
+201.05%
10 Year Est. Return
+1,210.21%
AUM
$2.05B
AUM Growth
+$251M
Cap. Flow
-$4.74M
Cap. Flow %
-0.23%
Top 10 Hldgs %
55.42%
Holding
131
New
4
Increased
20
Reduced
45
Closed
9

Top Buys

Rank Stock Value
1
ACH
Accendra Health
ACH
+$14.1M
2
IART icon
Integra LifeSciences
IART
+$11.6M
3
ENOV icon
Enovis
ENOV
+$10.8M
4
OFIX icon
Orthofix Medical
OFIX
+$10.6M
5
QDEL icon
QuidelOrtho
QDEL
+$8.18M

Top Sells

Rank Stock Value
1
AMWD
American Woodmark
AMWD
+$19M
2
SIBN icon
SI-BONE Inc
SIBN
+$10M
3
SMTC icon
Semtech
SMTC
+$6.59M
4
ACLS icon
Axcelis
ACLS
+$5.36M
5
NATR icon
Nature's Sunshine
NATR
+$5.19M

Sector Composition

Rank Sector Weight
1 Technology 56.84%
2 Healthcare 18.92%
3 Industrials 12.9%
4 Consumer Discretionary 10.17%
5 Materials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HALO icon
101
Halozyme
HALO
$12.2B
$520K 0.03%
10,000
ICHR icon
102
Ichor Holdings
ICHR
$2.56B
$511K 0.02%
+26,000
New +$476K
HI
103
DELISTED
Hillenbrand
HI
$468K 0.02%
23,300
THRM icon
104
Gentherm
THRM
$1.27B
$424K 0.02%
15,000
PG icon
105
Procter & Gamble
PG
$339B
$398K 0.02%
2,500
-500
-17% -$81.6K
PRIM icon
106
Primoris Services
PRIM
$4.45B
$390K 0.02%
5,000
TELA icon
107
TELA Bio
TELA
$38.9M
$388K 0.02%
200,000
BANR icon
108
Banner Corp
BANR
$2.4B
$385K 0.02%
6,000
AMAT icon
109
Applied Materials
AMAT
$428B
$366K 0.02%
2,000
EW icon
110
Edwards Lifesciences
EW
$51.7B
$344K 0.02%
4,400
-2,100
-32% -$157K
NBHC icon
111
National Bank Holdings
NBHC
$1.9B
$338K 0.02%
9,000
FNF icon
112
Fidelity National Financial
FNF
$13.5B
$331K 0.02%
5,900
PFE icon
113
Pfizer
PFE
$153B
$276K 0.01%
11,400
-5,600
-33% -$131K
NVMI
114
Nova
NVMI
$12.5B
$275K 0.01%
+1,000
New +$203K
ZD icon
115
Ziff Davis
ZD
$1.98B
$253K 0.01%
8,350
NEOG icon
116
Neogen
NEOG
$2.5B
$249K 0.01%
52,000
-205,100
-80% -$1.18M
HROW icon
117
Harrow
HROW
$1.51B
$244K 0.01%
8,000
BMY icon
118
Bristol-Myers Squibb
BMY
$132B
$236K 0.01%
5,100
-5,000
-50% -$245K
CMBM
119
DELISTED
Cambium Networks
CMBM
$189K 0.01%
466,900
-1,500
-0.3% -$584
LAKE icon
120
Lakeland Industries
LAKE
$119M
$136K 0.01%
+10,000
New +$167K
CDXS icon
121
Codexis
CDXS
$158M
$122K 0.01%
50,000
LAB icon
122
Standard BioTools
LAB
$314M
$20.9K ﹤0.01%
17,457
-230,943
-93% -$256K
BBW icon
123
Build-A-Bear
BBW
$462M
-10,000
Closed -$372K
CDW icon
124
CDW
CDW
$17B
-3,000
Closed -$481K
CTRN icon
125
Citi Trends
CTRN
$605M
-107,028
Closed -$2.37M

Similar funds

Paradigm Capital Management Inc's Q2 2025 Portfolio in Review

As of Q2 2025, Paradigm Capital Management Inc held 131 positions worth $2.05B, up 14% from $1.8B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Paradigm Capital Management Inc's Q2 2025 filing shows 4 new, 20 increased, 45 reduced and 9 closed positions. Its largest new stake was Treace Medical Concepts: 268,161 shares worth $1.58M. The largest sale was American Woodmark, an estimated $19M.

By sector, the portfolio is most concentrated in Technology at 57% of assets, up from 54% a quarter earlier, followed by Healthcare and Industrials.

  • Paradigm Capital Management Inc's largest Q2 2025 buy was Treace Medical Concepts: 268,161 shares worth $1.58M.
  • Paradigm Capital Management Inc added most to Accendra Health in Q2 2025, an estimated $14.1M increase.
  • Paradigm Capital Management Inc's biggest Q2 2025 reduction was American Woodmark, cutting an estimated $19M.
  • Paradigm Capital Management Inc fully exited Semtech in Q2 2025, selling an estimated $6.59M.
  • Paradigm Capital Management Inc's ten largest holdings make up 55% of its $2.05B portfolio in Q2 2025.
  • Paradigm Capital Management Inc opened 4 new positions and closed 9 in Q2 2025.
  • Paradigm Capital Management Inc's portfolio value rose 14% quarter-over-quarter to $2.05B.

Based on Paradigm Capital Management Inc's 13F filing for Q2 2025, filed 14 Aug 2025.